Answers are grounded in this paper and cite their sources.
The observation in a few patients that gynecomastia developed during an antifungal therapy with 200 mg ketoconazole daily set the stage for a totally new application for this drug. By administering 400 mg ketoconazole orally, every 8 hr, serum testosterone levels in or close to the castrate range were obtained within 1 day in prostate cancer patients. In addition, the adrenal androgens androstenedione and dihydroepiandrosterone were dramatically reduced. The effect was due to an interaction with cytochrome P450‐dependent enzymes active in the sex steroid‐synthesizing organs. Clinical improvement and a lowering of acid phosphatase were achieved within the first few days in previously untreated patients, and long‐term objective responses were obtained. A remarkable subjective and objective response to ketoconazole high dose was noticed in several patients who no longer responded to previous hormonal manipulations. Tolerance to the therapy was acceptable. Long‐term side effects were mainly related to the mechanism of action. Hepatotoxicity was rare. In some cases, gastric intolerance interfered with the therapy. The observation during antifungal therapy of a very rare side effect, namely, gynecomastia, has thus opened up new perspectives for patients afflicted with one of the main male cancers.
No takes yet. Share an insight, caveat, or question.
Amery et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: